Skip to content
Patients
HCPs
X-twitter Instagram Youtube Icon-mail Tiktok
Follow on X
Home
Daily Updates

Categories

Mutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

This study characterizes the genomic and microenvironmental landscape of gastric intestinal metaplasia (IM), a premalign...

Continue ReadingMutational Signatures and Clonal Hematopoiesis in Intestinal Metaplasia across Countries with Varying Stomach Cancer Incidence.

Transcriptomic Subtypes Are Associated with Clinical Outcomes for Patients with Lung Adenocarcinoma Who Have Never Smoked.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:1 min read

This publication comments on work by Zhao and colleagues examining lung adenocarcinoma in never-smokers, a clinically im...

Continue ReadingTranscriptomic Subtypes Are Associated with Clinical Outcomes for Patients with Lung Adenocarcinoma Who Have Never Smoked.

Rationale for the Nodule Management Protocol of the Australian National Lung Cancer Screening Program.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:1 min read

This article outlines how Australia’s forthcoming National Lung Cancer Screening Program (NLCSP) has developed a tailo...

Continue ReadingRationale for the Nodule Management Protocol of the Australian National Lung Cancer Screening Program.

Phase 1 Study of Rezatapopt, a p53 Reactivator, in Y220C-Mutated Tumors.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

Study type and population - Phase 1, single‑arm, dose‑escalation and dose‑optimization trial of rezatapopt, an o...

Continue ReadingPhase 1 Study of Rezatapopt, a p53 Reactivator, in Y220C-Mutated Tumors.

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

Phase 3 DESTINY-Breast05 compared adjuvant trastuzumab deruxtecan (T‑DXd, 5.4 mg/kg) with trastuzumab emtansine (T‑D...

Continue ReadingTrastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.

What practicing pathologists and oncologists should know about the new computational pathology-based companion diagnostic tools.

  • Post category:Respiratory (Lung, Bronchus) System
  • Reading time:2 mins read

This Perspective article reviews how AI-based computational pathology tools are becoming true companion diagnostics rath...

Continue ReadingWhat practicing pathologists and oncologists should know about the new computational pathology-based companion diagnostic tools.
  • © Together4Cancer. All rights reserved.
  • Privacy Policy
  • Terms of Use